7R
7R8.F Replimune Group Inc
- Market cap
- EUR 1.94B
- P/E
- -
- P/B
- 10.06x
- ROE
- -123.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 7R8.F undervalued?
Graham numberThe Graham number of Replimune Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Replimune Group Inc fundamental analysis
No fundamental analysis for Replimune Group Inc yet.
Replimune Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range o…
Full company profileReplimune Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Replimune Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -9.65M | -19.2M | -30.9M | -56.2M | -80.0M | -115M | -174M | -233M | -260M | -318M | -248M |
| EBITDA | - | -19.1M | -30.8M | -50.2M | -76.1M | -114M | -167M | -206M | -235M | -302M | -238M |
| Net Income | -7.70M | -19.7M | -30.8M | -52.6M | -80.9M | -118M | -174M | -216M | -247M | -314M | -254M |
| EPS | -0.25 | -0.64 | -0.97 | -1.44 | -1.74 | -2.49 | -3.08 | -3.51 | -3.21 | -3.80 | -2.68 |
| Balance Sheet | |||||||||||
| Total Assets | 22.8M | 65.2M | 154M | 234M | 543M | 461M | 647M | 488M | 551M | 332M | 374M |
| Total Liabilities | 34.3M | 5.22M | 16.5M | 50.4M | 44.4M | 50.0M | 91.3M | 113M | 135M | 166M | 169M |
| Shareholders' Equity | -11.5M | 59.9M | 138M | 184M | 499M | 411M | 555M | 375M | 416M | 166M | 205M |
| Cash & Short-term Investments | 20.6M | 17.6M | 25.7M | 59.5M | 183M | 106M | 147M | 74.5M | 111M | 209M | 308M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.08M | -16.0M | -25.4M | -60.6M | -61.4M | -82.2M | -128M | -185M | -192M | -280M | -247M |
| Capital Expenditure | 238K | 136K | 2.60M | 6.54M | 2.39M | 2.34M | 2.27M | 5.66M | 6.69M | 4.22M | 166K |
| Free Cash Flow | - | -16.2M | -28.0M | -67.1M | -63.8M | -84.5M | -130M | -191M | -199M | -285M | -247M |
| Ratios | |||||||||||
| ROE | - | -32.9% | -22.4% | -28.6% | -16.2% | -28.7% | -31.4% | -57.6% | -59.5% | -188.9% | -123.9% |
| ROA | -33.8% | -30.2% | -20.0% | -22.5% | -14.9% | -25.6% | -27.0% | -44.2% | -44.9% | -94.4% | -67.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Replimune Group Inc dividends
Replimune Group Inc has not paid dividends in the last 9 fiscal years.
Who owns Replimune Group Inc
- Insiders 1.63%
- Institutions 98.37%
- Public & others 0.00%
- Shares outstanding 94.8M
- Free float 68.2M
Replimune Group Inc company profile
- Company name
- Replimune Group Inc
- Ticker
- 7R8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 465
- Fiscal year end
- March
- Address
- 500 Unicorn Park Drive, Woburn, MA, United States, 01801
- Phone
- 781 222 9600
- Website
- replimune.com
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group Inc management
10- Dr. Sushil Patel Ph.D.CEO & Director · born 1971
- Ms. Emily Luisa HillChief Financial Officer · born 1980
- Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical Officer · born 1966
- Mr. Philip Astley-Sparke F.S.A.Executive Chairman · born 1971
- Ms. Nina AragamChief Operations Officer
- Mr. Andrew SchwendenmanChief Accounting Officer & Treasurer · born 1976
- Ms. Arleen GoldenbergHead of Investor Relations
- Mr. Shawn Glidden J.D.Chief Legal Officer
- Mr. Camilo Garcia M.A., M.B.A.Chief Human Resource Officer
- Mr. Paul BullockChief Manufacturing Officer & Framingham Site Head